BCAX Form 144: 6,415 Shares Proposed Sale Valued $114,764

Bicara Therapeutics, Inc. (BCAX) filing a Form 144 reports a proposed sale of 6,415 common shares through UBS Financial Services on 10/09/2025 with an aggregate market value of $114,764.00.

Rhea-AI Filing Summary

Bicara Therapeutics, Inc. (BCAX) filing a Form 144 reports a proposed sale of 6,415 common shares through UBS Financial Services on 10/09/2025 with an aggregate market value of $114,764.00. The shares were acquired the same day by exercise of stock options and paid for in cash. The filing also discloses sales by the same person, Ivan Hyep, in the three prior days: 6,514 shares on 10/06/2025 ($118,356.12), 18,244 shares on 10/07/2025 ($332,385.61), and 5,627 shares on 10/08/2025 ($102,456.42), totaling $553,198.15 in gross proceeds. The issuer had 54,562,841 shares outstanding and the proposed transactions are to occur on the NASDAQ.

Positive

• 6,415 shares proposed for sale were acquired by option exercise on 10/09/2025
• Payment in cash for the exercised shares indicates immediate settlement capability
• Previous sales over 10/06/2025–10/08/2025 generated $553,198.15 in gross proceeds

Negative

• None.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Bicara Therapeutics' (BCAX) Form 144 disclose?

The Form 144 reports a proposed sale of 6,415 common shares on 10/09/2025 valued at $114,764.00, acquired by option exercise and paid in cash.

Who is selling BCAX shares according to the filing?

The seller named is Ivan Hyep, who also sold shares on 10/06/2025, 10/07/2025, and 10/08/2025.

How many BCAX shares were outstanding per the Form 144?

The filing lists 54,562,841 shares outstanding.

Through which broker will the BCAX shares be sold?

The proposed sale is through UBS Financial Services, Inc., 11 Madison Ave, New York, NY.

What were the gross proceeds from recent BCAX sales by the seller?

Three sales on 10/06/2025–10/08/2025 produced combined gross proceeds of $553,198.15.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/09/2025 - 04:31 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002034668
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Bicara Therapeutics Inc.
SEC File Number	001-42271
Address of Issuer	116 HUNTINGTON AVENUE SUITE 703 BOSTON MASSACHUSETTS 02116
Phone	617-468-4219
Name of Person for Whose Account the Securities are To Be Sold	Hyep Ivan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	6415	114764.00	54562841	10/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/09/2025	Exercise of stock options	Issuer			6415	10/09/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ivan Hyep 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116	Common	10/06/2025	6514	118356.12
Ivan Hyep 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116	Common	10/07/2025	18244	332385.61
Ivan Hyep 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116	Common	10/08/2025	5627	102456.42

144: Remarks and Signature

Remarks
Date of Notice	10/09/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/13/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc., as attorney-in-fact for Ivan Hyep
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)